Cargando…
Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas
PURPOSE: The preoperative distinction between uterine leiomyoma (LM) and leiomyosarcoma (LMS) is difficult, which may result in dissemination of an unexpected malignancy during surgery for a presumed benign lesion. An assay based on circulating tumor DNA (ctDNA) could help in the preoperative distin...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105159/ https://www.ncbi.nlm.nih.gov/pubmed/32232185 http://dx.doi.org/10.1200/PO.18.00409 |
_version_ | 1783512354278866944 |
---|---|
author | Przybyl, Joanna Spans, Lien Lum, Deirdre A. Zhu, Shirley Vennam, Sujay Forgó, Erna Varma, Sushama Ganjoo, Kristen Hastie, Trevor Bowen, Raffick Debiec-Rychter, Maria van de Rijn, Matt |
author_facet | Przybyl, Joanna Spans, Lien Lum, Deirdre A. Zhu, Shirley Vennam, Sujay Forgó, Erna Varma, Sushama Ganjoo, Kristen Hastie, Trevor Bowen, Raffick Debiec-Rychter, Maria van de Rijn, Matt |
author_sort | Przybyl, Joanna |
collection | PubMed |
description | PURPOSE: The preoperative distinction between uterine leiomyoma (LM) and leiomyosarcoma (LMS) is difficult, which may result in dissemination of an unexpected malignancy during surgery for a presumed benign lesion. An assay based on circulating tumor DNA (ctDNA) could help in the preoperative distinction between LM and LMS. This study addresses the feasibility of applying the two most frequently used approaches for detection of ctDNA: profiling of copy number alterations (CNAs) and point mutations in the plasma of patients with LM. PATIENTS AND METHODS: By shallow whole-genome sequencing, we prospectively examined whether LM-derived ctDNA could be detected in plasma specimens of 12 patients. Plasma levels of lactate dehydrogenase, a marker suggested for the distinction between LM and LMS by prior studies, were also determined. We also profiled 36 LM tumor specimens by exome sequencing to develop a panel for targeted detection of point mutations in ctDNA of patients with LM. RESULTS: We identified tumor-derived CNAs in the plasma DNA of 50% (six of 12) of patients with LM. The lactate dehydrogenase levels did not allow for an accurate distinction between patients with LM and patients with LMS. We identified only two recurrently mutated genes in LM tumors (MED12 and ACLY). CONCLUSION: Our results show that LMs do shed DNA into the circulation, which provides an opportunity for the development of ctDNA-based testing to distinguish LM from LMS. Although we could not design an LM-specific panel for ctDNA profiling, we propose that the detection of CNAs or point mutations in selected tumor suppressor genes in ctDNA may favor a diagnosis of LMS, since these genes are not affected in LM. |
format | Online Article Text |
id | pubmed-7105159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-71051592020-03-30 Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas Przybyl, Joanna Spans, Lien Lum, Deirdre A. Zhu, Shirley Vennam, Sujay Forgó, Erna Varma, Sushama Ganjoo, Kristen Hastie, Trevor Bowen, Raffick Debiec-Rychter, Maria van de Rijn, Matt JCO Precis Oncol Original Reports PURPOSE: The preoperative distinction between uterine leiomyoma (LM) and leiomyosarcoma (LMS) is difficult, which may result in dissemination of an unexpected malignancy during surgery for a presumed benign lesion. An assay based on circulating tumor DNA (ctDNA) could help in the preoperative distinction between LM and LMS. This study addresses the feasibility of applying the two most frequently used approaches for detection of ctDNA: profiling of copy number alterations (CNAs) and point mutations in the plasma of patients with LM. PATIENTS AND METHODS: By shallow whole-genome sequencing, we prospectively examined whether LM-derived ctDNA could be detected in plasma specimens of 12 patients. Plasma levels of lactate dehydrogenase, a marker suggested for the distinction between LM and LMS by prior studies, were also determined. We also profiled 36 LM tumor specimens by exome sequencing to develop a panel for targeted detection of point mutations in ctDNA of patients with LM. RESULTS: We identified tumor-derived CNAs in the plasma DNA of 50% (six of 12) of patients with LM. The lactate dehydrogenase levels did not allow for an accurate distinction between patients with LM and patients with LMS. We identified only two recurrently mutated genes in LM tumors (MED12 and ACLY). CONCLUSION: Our results show that LMs do shed DNA into the circulation, which provides an opportunity for the development of ctDNA-based testing to distinguish LM from LMS. Although we could not design an LM-specific panel for ctDNA profiling, we propose that the detection of CNAs or point mutations in selected tumor suppressor genes in ctDNA may favor a diagnosis of LMS, since these genes are not affected in LM. American Society of Clinical Oncology 2019-10-16 /pmc/articles/PMC7105159/ /pubmed/32232185 http://dx.doi.org/10.1200/PO.18.00409 Text en © 2019 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Reports Przybyl, Joanna Spans, Lien Lum, Deirdre A. Zhu, Shirley Vennam, Sujay Forgó, Erna Varma, Sushama Ganjoo, Kristen Hastie, Trevor Bowen, Raffick Debiec-Rychter, Maria van de Rijn, Matt Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas |
title | Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas |
title_full | Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas |
title_fullStr | Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas |
title_full_unstemmed | Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas |
title_short | Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas |
title_sort | detection of circulating tumor dna in patients with uterine leiomyomas |
topic | Original Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105159/ https://www.ncbi.nlm.nih.gov/pubmed/32232185 http://dx.doi.org/10.1200/PO.18.00409 |
work_keys_str_mv | AT przybyljoanna detectionofcirculatingtumordnainpatientswithuterineleiomyomas AT spanslien detectionofcirculatingtumordnainpatientswithuterineleiomyomas AT lumdeirdrea detectionofcirculatingtumordnainpatientswithuterineleiomyomas AT zhushirley detectionofcirculatingtumordnainpatientswithuterineleiomyomas AT vennamsujay detectionofcirculatingtumordnainpatientswithuterineleiomyomas AT forgoerna detectionofcirculatingtumordnainpatientswithuterineleiomyomas AT varmasushama detectionofcirculatingtumordnainpatientswithuterineleiomyomas AT ganjookristen detectionofcirculatingtumordnainpatientswithuterineleiomyomas AT hastietrevor detectionofcirculatingtumordnainpatientswithuterineleiomyomas AT bowenraffick detectionofcirculatingtumordnainpatientswithuterineleiomyomas AT debiecrychtermaria detectionofcirculatingtumordnainpatientswithuterineleiomyomas AT vanderijnmatt detectionofcirculatingtumordnainpatientswithuterineleiomyomas |